gip glp 1 agonists GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications GLP-1 Receptor Agonists Explained for

Expert Opin Drug Discovery (2015) 10:82539

The ability of GLP-1 RAs to passivate or stabilise plaque requires further evaluation in human studies but may be a novel and important mechanism by which this class confers a reduced risk of future and recurrent ischaemic events, including both MI and ischaemic stroke

Evidence from Clinical Trials Clinical trials investigating the efficacy of GLP-1 agonists have revealed promising results

This is a real game-changer for the development of GLP-1 RAs and peptide therapeutics more broadly

Researchers said it therefore makes sense that weight loss from GLP-1 use could deliver better results for breast cancer patients

Eli Lilly, on the other hand, is making strides with its clinically superior drugs and is expected to surpass Novo Nordisk